Blog
RSS FeedPosted by Michael Wonder on 02 Aug 2016
Rare cancer drug which significantly delays progression of advanced thyroid cancer is left off relaunched Cancer Drugs Fund
2 August 2016 - People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima (lenvatinib mesylate) is not scheduled for ...
Posted by Michael Wonder on 02 Aug 2016
Call for NHS to haggle with drug companies over price of new treatments
1 August 2016 - Opposition politicians are calling for the Scottish NHS to haggle with drug companies over the price of ...
Posted by Michael Wonder on 02 Aug 2016
Afatinib dimaleate for patients with advanced squamous cell carcinoma of the lung: additional clinical benefits not there says IQWiG
1 August 2016 - Submitted comparisons for the benefit assessment are unsuitable. ...
Posted by Michael Wonder on 02 Aug 2016
Ospemifene in vulvovaginal atrophy: additional clinical benefits not seen says IQWiG
1 August 2016 - Incorrect study population, studies were too short. ...
Posted by Michael Wonder on 02 Aug 2016
Decision regarding funding of pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
2 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Merck Sharpe and Dohme (New Zealand) ...
Posted by Michael Wonder on 01 Aug 2016
Australia's most common and expensive drugs revealed by PBS data
1 August 2016 - They may be the most common drug in medicine cabinets across the country, but statins have been ...
Posted by Michael Wonder on 01 Aug 2016
Combination drugs taking flow-on price deductions for 1 October 2016
1 August 2016 - Combination drugs taking flow-on price reductions for 1 October 2016 have been published. ...
Posted by Michael Wonder on 01 Aug 2016
Make drug makers pay: England’s strategy for cancer medicines
29 July 2016 - Roche, Pfizer concerned new system has no spending limit. ...
Posted by Michael Wonder on 31 Jul 2016
CADTH recommends reimbursement of Eylea
27 July 2016 - CADTH has recommended that Bayer's aflibercept (Eylea) be reimbursed in Canada. ...
Posted by Michael Wonder on 31 Jul 2016
Schedule of Pharmaceutical Benefits - 1 August 2016 update
1 August 2016 - The August 2016 issue of the Schedule of Pharmaceutical Benefits is now available and in effect. ...
Posted by Michael Wonder on 31 Jul 2016
New Zealand Pharmaceutical Schedule - 1 August 2016 update
1 August 2016 - The August 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Jul 2016
CADTH recommends reimbursement of Revestive
29 July 2016 - CADTH has recommended that Shire's teduglutide (Revestive) be reimbursed in Canada. ...
Posted by Michael Wonder on 30 Jul 2016
A pill too hard to swallow: how the NHS is limiting access to high priced drugs
27 July 2016 - A joint investigation by The BMJ and Cambridge and Bath universities uncovers how NHS England tried to ...
Posted by Michael Wonder on 30 Jul 2016
High cost of new drugs
27 July 2016 - Why government must negotiate a better deal for publicly funded research. ...
Posted by Michael Wonder on 30 Jul 2016
Hollow victories and hepatitis C
28 July 2016 - When Gilead Sciences introduced sofosbuvir based antivirals in 2014, the drugs were touted as a breakthrough for ...